JNJ’s $4bn payout may not be the end of hip lawsuits
This article was originally published in Clinica
Executive Summary
Johnson & Johnson’s reconstructive implants franchise may have been the one bright spot in an otherwise sluggish third quarter for the overall medtech division but these devices – specifically, hip implants – are now going to cost the healthcare giant over $4bn in legal fees.